Friday, 29/08/2008

Skip navigation

Glossary | Site Map | Text Size: S L |

Product Pipeline Chart

MedImmune Cambridge-derived Clinical Development, Spring 2008
Partners Product Target Disease PreC  PhI PhII PhIII Fld Mkt
MedImmune CAT-8015 CD22 hairy cell leukaemia            
MedImmune CAT-8015 CD22 chronic lymphocytic leukaemia            
MedImmune CAT-8015 CD22 non-Hodgkin's lymphoma            
MedImmune CAT-354 IL-13 severe asthma            
MedImmune CAT-2200 IL17 rheumatoid arthritis            
CAT/Genzyme GC-1008 TGFβ idiopathic pulmonary fibrosis            
CAT/Genzyme GC-1008 TGFβ malignant melanoma            
CAT/Zenyth CAM-3001 GM-CSF receptor rheumatoid arthritis            
Abbott HUMIRA® TNFα rheumatoid arthritis            
Abbott HUMIRA® TNFα early rheumatoid arthritis            
Abbott HUMIRA® TNFα psoriatic arthritis            
Abbott HUMIRA® TNFα ankylosing spondylitis            
Abbott HUMIRA® TNFα Crohn's disease            
Abbott HUMIRA® TNFα juvenile rheumatoid arthritis            
Abbott HUMIRA® TNFα chronic plaque psoriasis            
Abbott HUMIRA® TNFα ulcerative colitis            
Abbott ABT-874 IL-12 Crohn's disease            
Abbott ABT-874 IL-12 psoriasis            
HGSI LymphoStat-B™ BLyS systemic lupus erythematosus            
HGSI LymphoStat-B™ BLyS rheumatoid arthritis            
HGSI HGS-ETR1 TRAIL-R1 non small-cell lung cancer            
HGSI HGS-ETR1 TRAIL-R1 non Hodgkin's lymphoma            
HGSI HGS-ETR1 TRAIL-R1 advanced colorectal cancer            
HGSI HGS-ETR1 TRAIL-R1 myeloma (+ chemotherapy)            
HGSI HGS-ETR1 TRAIL-R1 solid tumours (+ chemotherapy)            
HGSI HGS-ETR1 TRAIL-R1 advanced solid tumours            
HGSI HGS-ETR2 TRAIL-R2 advanced solid tumours            
HGSI ABthrax™ b.anthracis anthrax infection            
Wyeth MYO-029 GDF-8 muscular dystrophy   I/II        
iCo CAT-213 eotaxin1 allergic conjuntivitis            
MedImune's (formerly CAT's) patent licensees are developing the following human monoclonal antibody drug candidates
Dyax/ImClone IMC-11F8 EGFR solid tumours            
Dyax/ImClone IMC-1121B VEGFR-2 solid tumours            
Micromet/Serono MT201 Ep-CAM prostate cancer            
Micromet/Serono MT201 Ep-CAM metastatic breast cancer            
Micromet/Serono MT201 Ep-CAM relapsed/primary refractory breast cancer            

 

Key to table 'MedImmune Cambridge-derived Clinical Development, Spring 2008'
MedImmune proprietary product
MedImmune (formerly CAT) collaborative product
Product developed by MedImmune (formerly CAT) licensee
PreC Pre-Clinical: studies that investigate the pharmacokinetics, efficacy and toxicity of a potential drug without using human subjects
PhI Phase I: initial trials in a small number of healthy volunteers to test the drug for safety and tolerability
PhII Phase II: controlled trials in a greater number of patients with the disease to test the drug for dosing regimen, safety and efficacy
PhIII Phase III: controlled trials in a large number of patients with the disease to better understand the drug's efficacy and side effects
Fld Filed: clinical trial data under review for approval to market drug
Mkt Market: product launched